News & Updates

The use of tumour necrosis factor-α inhibitor (TNFi) for inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) raises the risk of developing psoriasis by twofold as compared with conventional therapy, although the absolute risk remains modest, as reported in a study.

In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.

Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.